Nivolumab plus ipilimumab with chemo for advanced lung cancer
Part of Lungs & breathing clinical trials.
This trial tests combining two immunotherapy drugs (nivolumab and ipilimumab) with chemotherapy as a first treatment for advanced lung cancer that has spread or come back. It may help if your cancer hasn't been treated before and doesn't have certain genetic changes.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have advanced (stage IV) or recurrent non-small cell lung cancer (NSCLC), confirmed by biopsy or cell sample.
- Your doctor has decided to start treatment with nivolumab plus ipilimumab combined with two cycles of platinum chemo, according to Italian guidelines.
- Your tumor does not have a sensitizing EGFR mutation or ALK translocation.
- You are at least 18 years old.
- You agree to join the study and sign a consent form.
- You have not been treated before with nivolumab or ipilimumab, and you are not already in another trial for your lung cancer.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This Phase 2 trial tests a combination of immunotherapy (nivolumab and ipilimumab) plus chemotherapy in people with advanced or non-removable lung cancer. It focuses on participants who also have specific viral infections (HIV, certain past/resolved hepatitis infections, and/or Long Covid), and it aims to see if this treatment improves cancer control and symptoms.
This trial tests a three-drug combination (ipilimumab, nivolumab, and nogapendekin alfa inbakicept) as a first treatment for people with stage IV or recurrent non-small cell lung cancer. The goal is to see if this approach can help your immune system fight the cancer more effectively.
This study compares two standard treatments for metastatic non-small cell lung cancer when the tumor has low levels of a protein called PD-L1. It looks at how well chemotherapy plus pembrolizumab works versus chemotherapy plus nivolumab and ipilimumab.
This trial tests whether a lower dose of the immunotherapy drug nivolumab combined with standard chemotherapy works better than chemotherapy alone for people with advanced or metastatic non-small cell lung cancer (NSCLC) that has not been treated before.
This trial tests a lower dose of the immunotherapy drug nivolumab (Opdivo) combined with standard chemotherapy before surgery for patients with early-stage non-small cell lung cancer (NSCLC). The goal is to see if this combination shrinks the tumor and improves outcomes with fewer side effects.
This trial is comparing a new combination of two immunotherapy drugs (nivolumab and relatlimab) plus chemotherapy against the standard immunotherapy (pembrolizumab) plus chemotherapy for people with advanced non-squamous non-small cell lung cancer that has a certain protein (PD-L1) on at least 1% of its cells. The goal is to see if the new combination works better.
Hear when a new Non Small Cell Lung Cancer Metastatic trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.